Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 281 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care probably leads to lower clinical worsening: participants admitted to hospital or deceased at… compared with standard care (plus/minus placebo) (moderate certainty).
The review found no eligible studies for this question.
Remdesivir and standard care may leads to lower serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in all‐cause mortality at up to day 60 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in in‐hospital mortality at up to day 150 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care probably leads to higher clinical improvement: participants alive and ready to be discharged… compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care probably leads to lower clinical worsening: time to new need for invasive mechanical… compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
Remdesivir and standard care showed no clear difference in serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
It is very uncertain whether remdesivir and standard care changes clinical improvement: participants with symptom alleviation at up to… compared with standard care (plus/minus placebo) (very low certainty).
Hyperimmune immunoglobulin from human plasma showed no clear difference in all‐cause mortality at day 28 compared with saline placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in improvement of clinical status (number of participants discharged… compared with saline placebo (low certainty).
The review found no eligible studies for this question.
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
It is very uncertain whether hyperimmune immunoglobulin from human plasma changes worsening of clinical status at day 28 (data only available for… compared with saline placebo (very low certainty).